Loading...
Lack of Clinically Significant Pharmacokinetic Interaction between the Thrombopoietin Receptor Agonist Eltrombopag and Hepatitis C Virus Protease Inhibitors Boceprevir and Telaprevir
Eltrombopag is an orally bioavailable thrombopoietin receptor agonist approved for the treatment of thrombocytopenia associated with chronic immune (idiopathic) thrombocytopenic purpura and chronic hepatitis C virus (HCV) infection. This study evaluated the potential drug-drug interactions between e...
Na minha lista:
| Udgivet i: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Microbiology
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4249398/ https://ncbi.nlm.nih.gov/pubmed/25155600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.03091-14 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|